Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer addresses investor concerns over the $68 billion mega merger at a follow up meeting Jan. 27.
You may also be interested in...
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.